Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines

Journal of the American Society of Nephrology

Volumn 15, Issue 11, 2004, Pages 2893-2901

  Langer, Robert ^a   Wang, Mouer ^a   Stepkowski, Stanislaw M ^a   Hancock, Wayne W ^b   Han, Rongxiang ^b   Li, Ping ^c   Feng, Lily ^c   Kirken, Robert A ^a   Berens, Kurt L ^d   Dupre, Brian ^d   Podder, Hemangshu ^a   Dixon, Richard A F ^d   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMOSIAMOSE; CALCINEURIN INHIBITOR; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE CCL20; CX3C CHEMOKINE; CYCLOSPORIN; CYCLOSPORIN A; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FINGOLIMOD; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; L SELECTIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; RAPAMYCIN; SELECTIN ANTAGONIST; SIALYL LEWIS X ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 1,6 BIS(3 (3 CARBOXYMETHYLPHENYL) 4 (2 ALPHA D MANNOPYRANOSYLOXY)PHENYL)HEXANE; 1,6-BIS(3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYLOXY)PHENYL)HEXANE; DRUG DERIVATIVE; HEXANE; IMMUNOSUPPRESSIVE AGENT; MANNOSE; SELECTIN;

ADDITION REACTION; ALLOGRAFT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BLOOD VESSEL; CELL ADHESION; CELL INFILTRATION; CYTOKINE PRODUCTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY ISCHEMIA; LEUKOCYTE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; REPERFUSION INJURY; RIBONUCLEASE PROTECTION ASSAY; ANIMAL; KIDNEY; KIDNEY TRANSPLANTATION; MALE; METABOLISM; PATHOLOGY; RAT STRAIN; VASCULARIZATION;

ANIMALS; CHEMOKINES; CYCLOSPORINE; CYTOKINES; DRUG SYNERGISM; GRAFT REJECTION; GRAFT SURVIVAL; HEXANES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MANNOSE; RATS; RATS, INBRED STRAINS; REPERFUSION INJURY; SELECTINS; SIROLIMUS;

EID: 16644369039     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000142425.23036.AC     Document Type: Article

References (49)

1. Hordijk P: Endothelial signaling in leukocyte transmigration. Cell Biochem Biophys 38: 305-322, 2003
2. Mellado M, Rodriguez-Frade JM, Manes S, Martinez-AC. Chemokine signaling and functional responses: The role of receptor dimerization and TK pathway activation. Annu Rev Immunol 19: 397-421, 2001
3. Burne-Taney MJ, Rabb H: The role of adhesion molecules and T cells in ischemic renal injury. Curr Opin Nephrol Hypertens 12: 85-90, 2003
4. Weis M, von Scheidt W: Cardiac allograft vasculopathy: A review. Circulation 96: 2069-2077, 1997
5. Butcher EC: Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity. Cell 67: 1033-1036, 1991
6. Kannagi R: Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr Opin Struct Biol 12: 599-608, 2002
7. Bevilacqua MP: Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 11: 767-804, 1993
8. Frenette PS, Mayadas TN, Rayburn H, Hynes RO, Wagner DD: Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell 84: 563-574, 1996
9. Tracey JB, Rinder HM: Characterization of the P-selectin ligand on human hematopoietic progenitors. Exp Hematol 24: 1494-1500, 1996
10. Moore KL: Structure and function of P-selectin glycoprotein ligand-1. Leuk Lymphoma 29: 1-15, 1998
11. Burch EE, Patil VR, Camphausen RT, Kiani MF, Goetz DJ: The N-terminal peptide of PSGL-1 can mediate adhesion to trauma-activated endothelium via P-selectin in vivo. Blood 100: 531-538, 2002
12. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 57: 1995
13. Baggiolini M, Dewald B, Moser B: Human chemokines: An update. Annu Rev Immunol 15: 675-705, 1997
14. Cyster JG: Chemokines and cell migration in secondary lymphoid organs. Science 286: 2098-2102, 1999
15. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, Bronson RT, Springer TA: Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A 95: 9448-9453, 1998
16. Kim CH, Broxmeyer HE: Chemokines: Signal lamps for trafficking of T and B cells for development and effector function. J Leukoc Biol 65: 6-15, 1999
17. Zhou Y, Genbacev O, Fisher SJ: The human placenta remodels the uterus by using a combination of molecules that govern vasculogenesis or leukocyte extravasation. Ann N Y Acad Sci 995: 73-83, 2003
18. Kogan TP, Dupre B, Bui H, McAbee KL, Kassir JM, Scott IL, Hu X, Vanderslice P, Beck PJ, Dixon RA: Novel synthetic inhibitors of selectin-mediated cell adhesion: Synthesis of 1,6-bis[3-(3-carboxymethylphenyl)- 4-(2-alpha-D-mannopyranosyloxy)phenyl]hexane (TBC1269). J Med Chem 41: 1099-1111, 1998
19. Davenpeck KL, Berens KL, Dixon RA, Dupre B, Bochner BS: Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: Preferential activity against neutrophil adhesion in vitro. J Allergy Clin Immunol 105: 769-775, 2000
20. Nemoto T, Burne MJ, Daniels F, O'Donnell MP, Crosson J, Berens K, Issekutz A, Kasiske BL, Keane WF, Rabb H: Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int 60: 2205-2214, 2001
21. Ramos-Kelly JR, Toledo-Pereyra LH, Jordan J, Rivera-Chavez F, Rohs T, Holevar M, Dixon RA, Yun E, Ward PA: Multiple selectin blockade with a small molecule inhibitor downregulates liver chemokine expression and neutrophil infiltration after hemorrhagic shock. J Trauma 49: 92-100, 2000
22. Subramanian S, Bowyer MW, Egan JC, Knolmayer TJ: Attenuation of renal ischemia-reperfusion injury with selectin inhibition in a rabbit model. Am J Surg 178: 573-576, 1999
23. Inman SR, Plott WK, Richardson BF, Lewis RM: Iohexol clearance is an accurate and reliable measure of glomerular filtration rate in rats [Abstract]. J Am Soc Nephrol 8: 347A, 1997
24. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G: Plasma clearance of non-radioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 6: 257-263, 1995
25. Chou TC, Kahan BD: A rigorous approach to the diagnosis of immunosuppressive synergy combination therapies. In: Modern Immunosuppressives: Milestones in Drug Therapy, edited by Schuurman H-J, Switzerland, Birkhauser, 2001 pp 183-200
26. Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984
27. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987
28. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, Nourse J, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 80: S40-S45, 1996
29. Huang S, Bjornsti MA, Houghton PJ: Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2: 222-232, 2003
30. Henning G, Ohl L, Junt T, Reiterer P, Brinkmann V, Nakano H, Hohenberger W, Lipp M, Forster R: CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: Modulation by FTY720. J Exp Med 194: 1875-1881, 2001
31. Vestweber D, Blanks JE: Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 19: 181-213, 1999
32. Bjorkdahl O, Barber KA, Brett SJ, Daly MG, Plumpton C, Elshourbagy NA, Tite JP, Thomsen LL: Characterization of CC-chemokine receptor 7 expression on murine T cells in lymphoid tissues. Immunology 110: 170-179, 2003
33. Haddad W, Cooper CJ, Zhang Z, Brown JB, Zhu Y, Issekutz A, Fuss I, Lee HO, Kansas GS, Barrett TA: P-selectin and P-selectin glycoprotein ligand 1 are major determinants for Th1 cell recruitment to nonlymphoid effector sites in the intestinal lamina propria. J Exp Med 198: 369-377, 2003
34. Zaph C, Scott P: Th1 cell-mediated resistance to cutaneous infection with Leishmania major is independent of P- and E-selectins. J Immunol 171: 4726-4732, 2003
35. Ohki S, Iizuka K, Ishikawa S, Kano M, Dobashi K, Yoshii A, Shimizu Y, Mori M, Morishita Y: A highly selective inhibitor of Rho-associated coiled-coil forming protein kinase, Y-27632, prolongs cardiac allograft survival of the BALB/c-to-C3H/He mouse model. J Heart Lung Transplant 20: 956-963, 2001
36. Szabo G, Bahrle S, Stumpf N, Sonnenberg K, Szabo EE, Pacher P, Csont T, Schulz R, Dengler TJ, Liaudet L, Jagtap PG, Southan GJ, Vahl CF, Hagl S, Szabo C: Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res 90: 100-106, 2002
37. Hancock WW: Chemokines and transplant immunobiology. J Am Soc Nephrol 13: 821-824, 2002
38. Pratschke J, Topham PS, Gao W, Paz D, Tilney NL, Gerard CJ, Hancock WW: New model of cold ischemia/reperfusion injury: CCR1 knockout mice are protected against renal injury [Abstract 961]. Presented at the XVIII Annual Scientific Meeting of the American Society of Transplantation, Chicago, IL, May 19-21, 1999
39. Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR, Fairchild-Huntress V, Fang Q, Dunmore JH, Huszar D, Pan Y: Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol 125: 59-65, 2002
40. Robinson LA, Nataraj C, Thomas DW, Howell DN, Griffiths R, Bautch V, Patel DD, Feng L, Coffman TM: A role for fractalkine and its receptor (CX(3)CR1) in cardiac allograft rejection. J Immunol 165: 6067-6072, 2000
41. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, Smiley ST, Ling M, Gerard NP, Gerard C: Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 192: 1515-1520, 2000
42. Haskell CA, Hancock WW, Salant DJ, Gao W, Csizmadia V, Peters W, Faia K, Fituri O, Rottman JB, Charo IF: Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 108: 679-688, 2001
43. Gao W, Topham PS, King JA, Smiley ST, Csizmadia V, Lu B, Gerard CJ, Hancock WW: Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 105: 35-44, 2000
44. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD: Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 193: 975-980, 2001
45. Dunn J, Grevel J, Napoli K, Lewis RM, Van Buren CT, Kahan BD: The impact of steady-state cyclosporine concentrations on renal allograft outcome. Transplantation 49: 30-34, 1990
46. Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS, Oppermann S, Kahan BD, Morrisett JD: Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 72: 1244-1250, 2001
47. Henning G, Ohl L, Junt T, Reiterer P, Brinkmann V, Nakano H, Hohenberger W, Lipp M, Forster R: CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: Modulation by FTY720. J Exp Med 194: 1875-1881, 2001
48. Wang ME, Tejpal N, Qu X, Yu J, Okamoto M, Stepkowski SM, Kahan BD: Immunosuppressive effects of FTY720 alone or in combination with cyclosporine or sirolimus. Transplantation 65: 899-905, 1998
49. Anselmo DM, Amersi FF, Shen XD, Gao F, Katori M, Lassman C, Ke B, Coito AJ, Ma J, Brinkmann V, Busuttil RW, Kupiec-Weglinski JW, Farmer DG: FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am J Transplant 2: 843-849, 2002